drugset / Trial / NCT01050699
Sleep Intervention During Acute Lung Injury
Phase 4
Completed
90 enrolled
University of Arizona
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The central purpose of this proposal is to study the short-term effects of sedation with sympatholysis, using α2 adrenergic agent Dexmedetomidine, on sleep and inflammation in critically ill patients with Acute Lung Injury and Acute Respiratory Disorder Syndrome (ALI/ARDS). An additional objective is to determine the effect of Dexmedetomidine sedation on the in-vitro production of sleep-modulating inflammatory cytokines by peripheral blood mononuclear cells of critically ill patients with ALI/ARDS.
Timeline
- Start
- 2009-08
- Primary completion
- 2019-01
- Completion
- 2019-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 0.5 ug/kg | Intravenous |
| Comparator | Fentanyl | Other / unclassified | 50 ug | Intravenous |
| Comparator | Fentanyl | Other / unclassified | 300 ug | Intravenous |
| Comparator | Midazolam | Small molecule | 1 mg | Intravenous |
| Comparator | Midazolam | Small molecule | 7 mg | Intravenous |